Nanoformulated alpha-mangostin ameliorates Alzheimer's disease neuropathology by elevating LDLR expression and accelerating amyloid-beta clearance

Biodegradable Long-Circulating Polymeric Nanospheres

Ruxandra Gref, Yoshiharu Minamitake, Maria Teresa Peracchia et al. · Science · 1994 · 2.9K citations

Pharmacy, Biomedical Engineering, Pharmaceutics +17

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Neurology, Pharmacology +17

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Neurology, Neuroscience +14

Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease

Mark J. West, Paul D. Coleman, Dorothy G. Flood et al. · The Lancet · 1994 · 1.3K citations · Full text

Life Sciences, Neurobiology, Neuroscience +15

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali et al. · Science Translational Medicine · 2012 · 1.1K citations

Pharmacy, Pharmaceutics, Pharmacology +17